Clinical features, tumor biology and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Diffuse Large B-cell Lymphomas of Immunoblastic Type Are a Major Reservoir for MYC-IGH Translocations

(2015) Heike Horn et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

MYC Cytogenetic Status Correlates With Expression and Has Prognostic Significance in Patients With MYC/BCL2 Protein Double-positive Diffuse Large B-cell Lymphoma

(2015) Xuan Julia Wang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Genetic lesions in diffuse large B-cell lymphomas

(2015) M. Testoni et al.   ANNALS OF ONCOLOGY

Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma

(2015) H Horn et al.   LEUKEMIA

Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions

(2015) Chi Young Ok et al.   MODERN PATHOLOGY

Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma

(2015) Jiayu Chen et al.   Oncotarget

Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma

(2014) J. Iqbal et al.   BLOOD

A clinician's guide to double hit lymphomas

(2014) Chan Yoon Cheah et al.   BRITISH JOURNAL OF HAEMATOLOGY

MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab

(2014) Anamarija M. Perry et al.   BRITISH JOURNAL OF HAEMATOLOGY

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

(2013) Z. Y. Xu-Monette et al.   BLOOD

MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?

(2013) C. Thieblemont et al.   BLOOD

Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification

(2013) G. Ott et al.   BLOOD

Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation

(2013) C. Huang et al.   BLOOD

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

(2013) H. Horn et al.   BLOOD

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

(2013) S. Hu et al.   BLOOD

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

(2013) S. M. Aukema et al.   HAEMATOLOGICA

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

(2013) A. Valera et al.   HAEMATOLOGICA

SMAD regulatory networks construct a balanced immune system

(2013) Nidhi Malhotra et al.   IMMUNOLOGY

Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

(2013) Alexandar Tzankov et al.   MODERN PATHOLOGY

High Levels of Nuclear MYC Protein Predict the Presence of MYC Rearrangement in Diffuse Large B-cell Lymphoma

(2012) Tina Marie Green et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

(2012) M. Chesi et al.   BLOOD

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

(2012) Z. Y. Xu-Monette et al.   BLOOD

c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells

(2012) Zuqin Nie et al.   CELL

Transcriptional Amplification in Tumor Cells with Elevated c-Myc

(2012) Charles Y. Lin et al.   CELL

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

(2012) C. Visco et al.   HAEMATOLOGICA

Growing Importance of MYC/BCL2 Immunohistochemistry in Diffuse Large B-Cell Lymphomas

(2012) Michael Pfreundschuh   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Nathalie A. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

BCL6 positively regulates AID and germinal center gene expression via repression of miR-155

(2012) Katia Basso et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

(2012) C Visco et al.   LEUKEMIA

The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers

(2012) Dinis Pedro Calado et al.   NATURE IMMUNOLOGY

Novel Smad proteins localize to IR-induced double-strand breaks: interplay between TGFβ and ATM pathways

(2012) Minli Wang et al.   NUCLEIC ACIDS RESEARCH

Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas

(2012) Michael J. Kluk et al.   PLoS One

Role of Smad Proteins in Resistance to BMP-Induced Growth Inhibition in B-Cell Lymphoma

(2012) Kanutte Huse et al.   PLoS One

MicroRNA signatures in B-cell lymphomas

(2012) L Di Lisio et al.   Blood Cancer Journal

Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

(2011) Nalan Akyurek et al.   CANCER

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas

(2011) Gustavo Tapia et al.   HISTOPATHOLOGY

MicroRNA-21 Limits In Vivo Immune Response-Mediated Activation of the IL-12/IFN-  Pathway, Th1 Polarization, and the Severity of Delayed-Type Hypersensitivity

(2011) T. X. Lu et al.   JOURNAL OF IMMUNOLOGY

Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC

(2011) T Holien et al.   LEUKEMIA

MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4

(2011) K Schramedei et al.   ONCOGENE

Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

(2010) Sharon Barrans et al.   JOURNAL OF CLINICAL ONCOLOGY

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

(2009) N. A. Johnson et al.   BLOOD

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

(2009) K. J. Savage et al.   BLOOD

BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome

(2009) Maria Grazia Tibiletti et al.   HUMAN PATHOLOGY

Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment

(2009) E C Obermann et al.   JOURNAL OF CLINICAL PATHOLOGY

MicroRNA-155 Suppresses Activation-Induced Cytidine Deaminase-Mediated Myc-Igh Translocation

(2008) Yair Dorsett et al.   IMMUNITY